Epidemiological studies on feline leukaemia virus infection. I. A serological survey in urban cats

Rogerson, Petrina; Jarrett, W. F. H.; Mackey, Lindsay

doi:10.1002/ijc.2910150509

Cited by 24 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the high prevalence of FeLV in the stray cat population (40%) increases the risk of infection for indoor–outdoor cats compared to indoor-only cats. Similarly, animal-to-animal contact contributes to the different rates of FeLV infection in single cat households (4%–11%) compared to multicat households whose prevalence has been reported to be as high as 70% 2,4,5…”

Section: Epidemiologymentioning

confidence: 99%

Broadening the use of antiretroviral therapy: the case for feline leukemia virus

Greggs¹,

Clouser²,

Patterson³

et al. 2011

TCRM

View full text Add to dashboard Cite

Antiretroviral drugs have saved and extended the lives of millions of individuals infected with HIV. The major classes of anti-HIV drugs include reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, and entry/fusion inhibitors. While antiretroviral drug regimens are not commonly used to treat other types of retroviral infections, there are instances where there is a perceived need for re-evaluation of the benefits of antiretroviral therapy. One case in point is that of feline leukemia virus (FeLV), an infection of companion felines. While vaccines exist to prevent FeLV infection and spread, they have not eliminated FeLV infection. For FeLV-infected felines and their human companions, antiretroviral therapy would be desirable and of practical importance if good options were available. Here, we discuss FeLV biology and current treatment options, and propose that there is a need for antiretroviral treatment options for FeLV infection. The comparative use and analysis of antiretroviral therapy can provide new insights into the mechanism of antiretroviral drug action.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Broadening the use of antiretroviral therapy: the case for feline leukemia virus

Greggs¹,

Clouser²,

Patterson³

et al. 2011

TCRM

View full text Add to dashboard Cite

show abstract

“…Serological survey of free-roaming urban domestic cats indicates that at least 50% of adult animals have been infected with FeLV (Rogerson et al, 1975). While most animals successfully clear the infection without disease consequences, the majority of persistently infected animals succumb to degenerative diseases including anemia or immunodeficiency, neoplastic or proliferative diseases including lymphoma, leukemia or myeloproliferative disorder (Mullins and Hoover, 1990;Rezanka et al, 1992).…”

Section: The Unique Ltr and Su Gene Sequences Of Felv-945 Act As Detementioning

confidence: 99%

Advances in understanding molecular determinants in FeLV pathology

Lévy

2008

Veterinary Immunology and Immunopathology

View full text Add to dashboard Cite

Feline leukemia virus (FeLV) occurs in nature not as a single genomic species but as a family of closely related viruses. The disease outcome of natural FeLV infection is variable and likely reflects genetic variation both in the virus and the naturally outbreeding host population. A series of studies have been undertaken with the objectives of examining natural FeLV genetic variation, the selective pressures operative in FeLV infection that lead to predominance of natural variants, and the consequences for infection and disease progression. Genetic variation among FeLV isolates was examined in a cohort of naturally infected cats with thymic lymphoma of T-cell origin, non-T-cell multicentric lymphoma, myeloproliferative disorder or anemia. The predominant isolate in the cohort, designated FeLV-945, was identified exclusively in disorders of non-T-cell origin. The FeLV-945 LTR was shown to contain a unique 21-bp repeat element, triplicated in tandem downstream of enhancer. The 21-bp triplication was shown to act as a transcriptional enhancer and to confer a replicative advantage through the assembly of a distinctive transcription factor complex. Oncogene utilization during tumor induction by FeLV-945 was studied using a recombinant Moloney murine leukemia virus containing the FeLV-945 LTR. This approach identified novel loci of common proviral integration in tumors, including the regulatory subunit of PI-3Kgamma. Mutational changes identified in FeLV-945 SU were shown not to alter receptor usage as measured by host range and superinfection interference, but to significantly increase the efficiency of receptor binding. To determine whether the unique sequence elements of FeLV-945 influence the course of infection and disease in vivo, recombinant viruses were constructed in which the FeLV-945 LTR alone, or the FeLV-945 SU gene and LTR were substituted into the prototype isolate FeLV-A/61E. Longitudinal studies of infected animals showed that substitution of the FeLV-945 LTR into FeLV-A/61E resulted in a significantly more rapid disease onset, but did not alter the tumorigenic spectrum. In contrast, substitution of both the FeLV-945 LTR and SU gene changed the disease outcome entirely. Together, these observations indicate that the distinctive LTR and SU gene of FeLV-945 mediate a rapid pathogenesis with distinctive clinical features and oncogenic mechanisms.

show abstract

“…FeLV is endemic in freeroaming urban domestic cats, serological survey of which shows that at least 50% of adult animals have been infected (27). The disease outcome of natural FeLV infection is variable and rather unpredictable.…”

mentioning

confidence: 99%

Unique Long Terminal Repeat and Surface Glycoprotein Gene Sequences of Feline Leukemia Virus as Determinants of Disease Outcome

Chandhasin

Coan²,

Pandrea

et al. 2005

J Virol

View full text Add to dashboard Cite

Epidemiological studies on feline leukaemia virus infection. I. A serological survey in urban cats

Cited by 24 publications

References 8 publications

Broadening the use of antiretroviral therapy: the case for feline leukemia virus

Broadening the use of antiretroviral therapy: the case for feline leukemia virus

Advances in understanding molecular determinants in FeLV pathology

Unique Long Terminal Repeat and Surface Glycoprotein Gene Sequences of Feline Leukemia Virus as Determinants of Disease Outcome

Contact Info

Product

Resources

About